Tienan Zhu
Peking Union Medical College Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Tienan Zhu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:12 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07400250 · Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of TherapyPeking Union Medical College Hospital · not yet recruiting · Primary Immune Thrombocytopenia (ITP) · principal investigator
- Ph2NCT06478537 · TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment TerminationPeking Union Medical College Hospital · recruiting · Immune Thrombocytopenia · principal investigator
- Ph4NCT05135442 · Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTPPeking Union Medical College Hospital · unknown · Thrombotic Thrombocytopenic Purpura, Acquired · study chair
- Ph2NCT03700229 · Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia APeking Union Medical College Hospital · unknown · Acquired Hemophilia A · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:12 UTC. The ranking covers the 200 most relevant of 253 PubMed records, and a shared surname and initials can bring in a namesake. All 253 on PubMed
- 1,425 citationsRCR 76.7
- 181 citationsRCR 11.0
- Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.AIDS Res Hum Retroviruses · 2000144 citationsRCR 2.9
- Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis.PLoS One · 2014131 citationsRCR 5.0
- Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.Nat Med · 2022131 citationsRCR 7.0
- Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial.Am J Obstet Gynecol · 2020115 citationsRCR 7.9
- Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients.Signal Transduct Target Ther · 2021106 citationsRCR 4.9
- Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.Antimicrob Agents Chemother · 201198 citationsRCR 3.1
- Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors.Ann Surg Oncol · 200193 citationsRCR 2.4
- A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma.Ann Thorac Surg · 200393 citationsRCR 3.0